Jane Street Group, LLC Next Cure, Inc. Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.17 - $2.49 $22,630 - $48,161	19,342 New	19,342 $30,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $3.07 $28,490 - $72,887	23,742 New	23,742 $33,000
Q2 2022 Aug 16, 2022	SELL	$3.38 - $5.27 $50,882 - $79,334	-15,054 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$4.76 - $6.24 $71,657 - $93,936	15,054 New	15,054 $73,000
Q3 2021 Nov 16, 2021	SELL	$6.74 - $8.02 $101,935 - $121,294	-15,124 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$7.6 - $10.28 $114,942 - $155,474	15,124 New	15,124 $121,000
Q3 2020 Nov 17, 2020	SELL	$8.15 - $21.17 $91,826 - $238,522	-11,267 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$21.19 - $40.2 $238,747 - $452,933	11,267 New	11,267 $242,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.